They received FDA approval so I would think they have some validity to them.
Not in a commercial sense.
There are many cases where a company gets FDA approval and then finds that there is no meaningful demand for the product; examples are SOMX’s Silenor, DDSS’ Oleptro, and FCSC’s Laviv. Note that two of these losers (Silenor and Oleptro) were reformulations of generic drugs, which is what IGXT has done.